Residents should consider the evidence behind alternative therapies used to control costs in such settings, e.g., use of streptokinase vs. recombinant tissue plasminogen activator (tPA) for thrombolysis in acute coronary syndrome and stroke. This evidence concerns the gene PLAT and stroke disorder.